Last modified by Asif Farooqui on 2021/04/15 09:39
From version < 6.2 >
edited by Asif Farooqui
on 2021/04/13 14:17
To version < 6.3
edited by Asif Farooqui
on 2021/04/15 09:39
<
Change comment: There is no comment for this version

Summary

Details

Page properties
Content
... ... @@ -152,7 +152,7 @@
152 152  
153 153  == Highlights for Q3 FY 2020-21 ==
154 154  
155 -February 12, 2021: : Glenmark Pharmaceuticals Limited announced its financial results for the third quarter ended December 31 of the financial year 2020-21. {{footnote}}https://www.glenmarkpharma.com/sites/default/files/Glenmarks-consolidated-sales-risesin-q3.pdf{{/footnote}}
155 +**February 12, 2021: : Glenmark Pharmaceuticals Limited announced its financial results for the third quarter ended December 31 of the financial year 2020-21.** {{footnote}}https://www.glenmarkpharma.com/sites/default/files/Glenmarks-consolidated-sales-risesin-q3.pdf{{/footnote}}
156 156  
157 157  For the third quarter of FY 2020-21, Glenmark’s consolidated sales was at Rs. 27,605.07 Mn. as against Rs. 26,574.51 Mn. recording an increase of 3.88 %.
158 158  
... ... @@ -170,7 +170,7 @@
170 170  
171 171  Sales from the formulation business in India for the Third Quarter of FY 2020-21 was at Rs. 8,821.19 Mn. as against Rs. 7,888.39 Mn. in the previous corresponding quarter, recording growth of 11.82 %.
172 172  
173 -The India business continues to significantly outperform industry growth rates, continuing the trend of the past several years. As per IQVIA data, Glenmark remains the second fastest growing company in the industry among the Top 20 players on a MAT Dec 2020 basis with growth of 15.8% as compared to IPM (Indian Pharma market) growth of 6.12%. On a quarterly basis, as per IQVIA, the business recorded growth of 15.11% as compared to 9.75% for the market. {{footnote}}https://www.glenmarkpharma.com/sites/default/files/Glenmarks-consolidated-sales-risesin-q3.pdf{{/footnote}}
173 +The India business continues to significantly outperform industry growth rates, continuing the trend of the past several years. As per IQVIA data, Glenmark remains the second fastest growing company in the industry among the Top 20 players on a MAT Dec 2020 basis with growth of 15.8% as compared to IPM (Indian Pharma market) growth of 6.12%. On a quarterly basis, as per IQVIA, the business recorded growth of 15.11% as compared to 9.75% for the market.
174 174  
175 175  
176 176  Glenmark Pharmaceuticals Inc., USA registered revenue from sale of finished dosage formulations of Rs.7,803.87 Mn. for the quarter ended Dec 31, 2020 as against revenue of Rs.7,998.28 Mn. for the previous corresponding quarter, recording decline in revenue by (2.43%). However, the business recorded quarter on quarter growth of 4.4 % in USD terms.
... ... @@ -210,7 +210,7 @@
210 210  = Recent developments =
211 211  
212 212  
213 -Glenmark Pharmaceuticals receives ANDA approval for Chlorpromazine Hydrochloride Tablets USP {{footnote}}https://www.glenmarkpharma.com/sites/default/files/Glenmark-receives-ANDA-approval-for-Chlorpromazine-Hydroch.pdf{{/footnote}}
213 +**Glenmark Pharmaceuticals receives ANDA approval for Chlorpromazine Hydrochloride Tablets USP** {{footnote}}https://www.glenmarkpharma.com/sites/default/files/Glenmark-receives-ANDA-approval-for-Chlorpromazine-Hydroch.pdf{{/footnote}}
214 214  
215 215  **March 24, 2021;** : Glenmark Pharmaceuticals Limited (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Chlorpromazine Hydrochloride Tablets USP, 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg, the generic version of Thorazine®1 Tablets, 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg, of GlaxoSmithKline. 
216 216  
This site is funded and maintained by Fintel.io